# Hyperpolarized MR Imaging With Carbon-13 Pyruvate in the Human Body

Study · id `cardio:ct-nct06645691` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06645691](<https://clinicaltrials.gov/study/NCT06645691>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT06645691

Browse, organ or system: Heart; Metabolism  
Browse, condition area: Heart failure; Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 200 participants.

## Technical summary

Registry record NCT06645691. Allocation not applicable; no masking; primary purpose diagnostic. Start 2024-10-17 (actual); primary completion 2028-05-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose diagnostic
- Phase: Phase 2
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT06645691, source copy `cardio:ctgov-nct06645691-2026-11-17`, retrieved 2026-11-18)
- Started: 2024-10-17 (actual) (ClinicalTrials.gov record NCT06645691, source copy `cardio:ctgov-nct06645691-2026-11-17`, retrieved 2026-11-18)
- Primary completion: 2028-05-31 (anticipated) (ClinicalTrials.gov record NCT06645691, source copy `cardio:ctgov-nct06645691-2026-11-17`, retrieved 2026-11-18)
- Completion: 2028-05-31 (anticipated) (ClinicalTrials.gov record NCT06645691, source copy `cardio:ctgov-nct06645691-2026-11-17`, retrieved 2026-11-18)
- Countries: Singapore (ClinicalTrials.gov record NCT06645691, source copy `cardio:ctgov-nct06645691-2026-11-17`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06645691-2026-11-17`, retrieved 2026-11-18)

## The registry's words

- Brief title: Hyperpolarized MR Imaging With Carbon-13 Pyruvate in the Human Body
- Acronym: POLARIC-13
- Condition: Heart Failure
- Condition: Cardiometabolic Syndrome
- Condition: Cancer Diagnosis
- Condition: Cardiovascular Diseases
- Condition: Healthy Volunteers
- Intervention (Drug): Hyperpolarized 13C-pyruvate
- Lead sponsor: National Heart Centre Singapore
- Lead sponsor class: OTHER
- Collaborator: National Medical Research Council (NMRC), Singapore
- Collaborator class: OTHER\_GOV

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition terms include this condition: Metabolic syndrome (`cardio:metabolic-syndrome`)
- Registry lists this organization as the lead sponsor: National Heart Centre Singapore (`cardio:org-national-heart-centre-singapore`)
- Registry lists this organization as a collaborator: National Medical Research Council (NMRC), Singapore (`cardio:org-national-medical-research-council-nmrc-singapore`)

## Provenance

Content hash: 4179fe9b1ab46cdfe6deee90bbf0f902ed38645b0f89bdc65d6a14bc8441c48f
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
